PMID- 17926797
OWN - NLM
STAT- MEDLINE
DCOM- 20071218
LR  - 20211203
IS  - 0890-9091 (Print)
IS  - 0890-9091 (Linking)
VI  - 21
IP  - 10
DP  - 2007 Sep
TI  - Evolving role of novel targeted agents in renal cell carcinoma.
PG  - 1175-80; discussion 1184, 1187, 1190
AB  - The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically 
      over the past few years. An improved understanding of the biology of RCC has 
      resulted in the development of novel targeted therapeutic agents that have 
      altered the natural history of this disease. In particular, the hypoxia-inducible 
      factor (HIF)/vascular endothelial growth factor (VEGF) pathway and the mammalian 
      target of rapamycin (mTOR) signal transduction pathway have been exploited. 
      Sunitinib malate (Sutent), sorafenib tosylate (Nexavar), bevacizumab 
      (Avastin)/interferon alfa, and temsirolimus (Torisel) have improved clinical 
      outcomes in randomized trials by inhibiting these tumorigenic pathways. 
      Combinations and sequences of these agents are being evaluated. Other novel 
      multitargeted tyrosine kinase inhibitors (pazopanib and axitinib) and mTOR 
      inhibitors (everolimus) are in clinical development. Recently reported and 
      ongoing clinical trials will help further define the role of these agents as 
      therapy for metastatic RCC.
FAU - Hutson, Thomas E
AU  - Hutson TE
AD  - Baylor Sammons Cancer Center, U.S. Oncology Research Network Dallas, Texas, USA.
FAU - Figlin, Robert A
AU  - Figlin RA
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Oncology (Williston Park)
JT  - Oncology (Williston Park, N.Y.)
JID - 8712059
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antiviral Agents)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Immunologic Factors)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Interleukin-2)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Antiviral Agents/therapeutic use
MH  - Bevacizumab
MH  - Carcinoma, Renal Cell/blood supply/drug therapy/*secondary/*therapy
MH  - Clinical Trials as Topic
MH  - Disease-Free Survival
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/antagonists & inhibitors/drug effects
MH  - Immunologic Factors/therapeutic use
MH  - Immunosuppressive Agents/therapeutic use
MH  - Interleukin-2/therapeutic use
MH  - Kidney Neoplasms/blood supply/drug therapy/*therapy
MH  - Neovascularization, Pathologic/*drug therapy/prevention & control
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein Kinases
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors/drug effects
RF  - 37
EDAT- 2007/10/12 09:00
MHDA- 2007/12/19 09:00
CRDT- 2007/10/12 09:00
PHST- 2007/10/12 09:00 [pubmed]
PHST- 2007/12/19 09:00 [medline]
PHST- 2007/10/12 09:00 [entrez]
AID - 169577 [pii]
PST - ppublish
SO  - Oncology (Williston Park). 2007 Sep;21(10):1175-80; discussion 1184, 1187, 1190.